Description of Research Expertise

My research interests focus on improving outcomes in patients with lymphomas using novel agents and immune based therapies. I have served as the principal investigator on several trials including multicenter investigator initiated trial using brentuximab (immunoconjugate) in combination with chemotherapy as frontline treatment for CD30+ B cell lymphomas. I have also conducted a pilot trial using chimeric antigen receptor (CAR) T cells in patients in relapsed/refractory Hodgkin lymphoma and served as co-investigator on trials using CAR T cells in non-Hodgkin lymphomas. More recently, I have been involved in collaborative work with our translational scientists which may allow us to find new therapeutic targets for cellular therapies in Hodgkin lymphoma.

Selected Publications

Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH.: Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas N Engl J Med 377 (26): 2545-2554,2017.

Jakub Svoboda, Steven M Bair, Daniel J Landsburg, Sunita Dwivedy Nasta, Sarah J Nagle, Stefan K Barta, Nadia Khan, Joanne Filicko-O'Hara, Sameh Gaballa, Lauren Strelec, Elise Chong, Sheryl Mitnick, Terease S Waite, Cara King, Hatcher Ballard, Matthew Youngman, James Gerson, John P Plastaras, Amit Maity, Agata M Bogusz, Stacy S Hung, Hisae Nakamura, Reza Nejati, Christian Steidl, Megan Lim, Marco Ruella, Stephen J Schuster: Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas Haematologica 106 (6): 1705,2021.

Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, Suhoski MM, Melenhorst JJ, Loudon B, Mato AR, Nasta SD, Landsburg DJ, Youngman MR, Levine BL, Porter DL, June CH, Schuster SJ.: Non-viral RNA chimeric antigen receptor modified T cells in patients with Hodgkin lymphoma. Blood 132 (10): 1022-1026,2018.

Ruan J1, Martin P1, Christos P2, Cerchietti L1, Tam W3, Shah B4, Schuster SJ5, Rodriguez A1, Hyman D1, Calvo-Vidal MN1, Smith SM6, Svoboda J4, Furman RR1, Coleman M1, Leonard JP1.: Five-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma. Blood 132 (19): 2016-2025,2018.

P Armand, S Rodig, V Melnichenko, C Thieblemont, K Bouabdallah, G Tumyan, M Özcan, S Portino, L Fogliatto, MD Caballero, J Walewski, Z Gulbas, V Ribrag, B Christian, GF Perini, G Salles, J Svoboda, J Zain, S Patel, PH Chen, AH Ligon, J Ouyang, D Neuberg, R Redd, A Chatterjee, A Balakumaran, R Orlowski, M Shipp, and PL Zinzani: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma J Clin Oncol. 37 (34): 3291-3299,2019.

Bair SM, Mato A, Svoboda J.: Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm. Clin Lymphoma Myeloma Leuk 18 (6): 380-391,2018.

Elise A Chong, Cécile Alanio, Jakub Svoboda, Sunita D Nasta, Daniel J Landsburg, Simon F Lacey, Marco Ruella, Siddharth Bhattacharyya, E John Wherry, Stephen J Schuster: Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy Blood, The Journal of the American Society of Hematology 139 (7): 1026-1038,2022.

G Ghilardi, EA Chong, J Svoboda, P Wohlfarth, SD Nasta, S Williamson, JD Landsburg, JN Gerson, SK Barta, R Pajarillo, J Myers, AI Chen, L Schachter, R Yelton, HJ Ballard, A Hodges Dwinal, S Gier, D Victoriano, E Weber, E Napier, A Garfall, DL Porter, U Jäger, RT Maziarz, M Ruella, SJ Schuster: Bendamustine is Safe and Effective for Lymphodepletion Before Tisagenlecleucel in Patients with Refractory or Relapsed Large B-Cell Lymphomas Annals of Oncology : 2022.

Miguel-Angel Perales, Larry D Anderson Jr, Tania Jain, Saad S Kenderian, Olalekan O Oluwole, Gunjan L Shah, Jakub Svoboda, Mehdi Hamadani: Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy Transplantation and Cellular Therapy 28 : 546-559,2022.

Carrie Ho, Marco Ruella, Bruce L Levine, Jakub Svoboda: Adoptive T-cell therapy for Hodgkin lymphoma Blood Advances 5 (20): 4291-4302,2021.

Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xaiver AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, and Svoboda, J.: R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol 180 (4): 534-544,2018.

Ruan J, Martin P, Shah B, Schuster SJ, Smith, SM, Furman RR, Christos P, Rodriguez A, Svoboda J, Lewis J, Katz O, Coleman M, Leonard, JP: Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma. New England Journal of Medicine 373 (19): 1835-44,2015.

Academic Contact Information

Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-179
3400 Civic Center Boulevard
Philadelphia, PA 19104
Phone: 215-614-1846
Patient appointments: 800-789-7366